• ABPI Website
  • Media
  • ABPI comment on Government's full response to the O'Shaughnessy Review

ABPI comment on Government's full response to the O'Shaughnessy Review

The ABPI has commented on the Government's full response to the O'Shaughnessy Review. 

Janet Valentine, Executive Director of Innovation and Research Policy for ABPI, said:

"The ABPI has long called for a delivery-focussed approach to getting UK industry clinical trials back on track, and today the Government has delivered a clear plan that will make a real difference to patients.

“We’ve got a long way to go if we want to see sustained recovery, and achieve the ambition set out in Lord O’Shaughnessy’s review to quadruple recruitment to industry clinical trials. But by continuing to streamline approvals and set-up, and expanding dedicated capacity, we now have a clear strategy to rebuild global confidence in the UK’s clinical research offer.

“In an environment where there is ever-growing international competition for industry investment in research, today’s response is very welcome, and we will continue to play our part in putting it into action so that more patients can participate in trials and benefit from innovative therapies.”

  • Clinical research

Last modified: 22 November 2023

Last reviewed: 22 November 2023

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.